Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit

Moderate to Severe Midface Volume Deficit Clinical Trial

Official title: Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit

Status Completed

Clinical Trial Summary

Evaluation of the sensitivity of the Merz Cheeks Fullness Assessment Scale (MCFAS) and the clinical relevance of aesthetically pleasing outcomes by detecting changes in cheek appearance after Belotero® Volume Lidocaine injection.

The safety objectives include the identification and description of adverse events (AEs), adverse device effects (ADEs), serious adverse events (SAEs), serious adverse device effects (SADEs), anticipated serious adverse device effects (ASADEs) and unanticipated adverse device effects (UADEs) during the course of the study. Additionally, common treatment site responses (CTRs) will be assessed.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Moderate to Severe Midface Volume Deficit

• NCT number: NCT03321825
• Study type: Interventional
• Source: Merz North America, Inc.
• Status: Completed
• Phase: N/A
• Start date: September 29, 2017
• Completion date: January 8, 2018